poly(lactic-co-glycolic acid PLGA 50 μm Preparation and release features of long-term slow-release two-component drug artificial bone

Transcript

1 Chinese Journal of Tissue Engineering Research September 16, 2012 Vol.16, No.38 doi: /j.issn [ [J] (38): * ( ) tjs.hhyywy@ yahoo.com.cn :R318 :B : (2012) ( /GW W) poly(lactic-co-glycolic acid PLGA 50 μm 26% 28% 50% 90 d mg/l Preparation and release features of long-term slow-release two-component drug artificial bone Bao Yu-cheng, Zhang Wen-long, Wang Yong, Zhang Jie Abstract BACKGROUND: Studies have shown that rifampicin or isoniazid covered with biodegradable sustained release materials can be used to prepare pulmonary targeting microspheres with less than 50 μm sustained-release degradation, which are mainly used for lung targeted therapy via the intravenous injection. OBJECTIVE: To develop long-term slow-release two-component drug artificial bone and to select the optimal preparation process of drug release as well as to observe the characteristics of in vitro releases. METHODS: Orthogonal design was adopted to optimize the preparation technology using the emulsion-solvent evaporation method of preparation technology. We prepared rifampicin poly(lactic-co-glycolic acid) copolymer microspheres and isoniazid poly(lactic-co-glycolic acid) copolymer microspheres. Biological binder was used to process these two kinds of microspheres into long-term slow-release two-component drug artificial bone. RESULTS AND CONCLUSION: According to the process optimization, two kinds of poly(lactic-co-glycolic acid) copolymer microspheres carrying 26% rifampicin or 28% isoniazid were prepared successfully, which were used to prepare artificial bone at a quality of 50%. The drug concentrations were kept at 0.02 and 0.03 mg/l after 90 days of in vitro release. These findings indicate that this kind of artificial bone is expected to provide a new and effective treatment for bone tuberculosis. Bao YC, Zhang WL, Wang Y, Zhang J. Preparation and release features of long-term slow-release two-component drug artificial bone. Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(38):

2 % 10% [1-2] [3-4] [5-6] [7] 50 μm [8-10] (poly (lactic-coglycolic acid) PLGA) μm PLGA μm PLGA ( ) / T PLGA( ) (DCM) (a- ) LC-10A () N-2000 OLYMPUS IX71 Japan PLGA PLGA [11-12] PLGA 700 mg10 ml 2% h PLGA4 (A) PLGA (B) (C) (D)3 1L 9 (3) 4 1 Table 1 Orthogonal experimental design factors and levels table Level T A ( ) PLGA/RFP B (ratio) Factor PVA C (%) Stirring speed D (r/min) : : : PLGA: poly(lactic-co-glycolic acid); RFP: rifampicin; PVA: polyvinyl alcohol; A: reaction temperature; B: PLGA and RFP quality ratio; C: the concentration of PVA mass fraction; D: mixing rate Bao Yu-cheng, Corresponding author: Wang Yong, Senior engineer, tjs.hhyywy@ yahoo.com.cn Supported by: the Science and Technology Foundation of Tianjin Health Bureau, No. 2010KY10* Received: Accepted: ISSN CN /R CODEN: ZLKHAH 7127

3 S 1 S 2 S(=S 1 +S 2 ) [13] S μm 500S 1 =( /) 100% S 2 =( / ) 100% PLGAPLGA PLGA μm 26% 1aPLGA μm 28% 1b 2 L 9 (3) 4 Table 2 L 9 (3) 4 orthogonal experimental design and results Test No Factor A B C D S 1 S 2 S K K K R a: PLGA microsphere carrying rifampicin A: reaction temperature; B: poly(lactic-co-glycolic acid) and rifampicin quality ratio; C: the concentration of polyvinyl alcohol mass fraction; D: mixing rate; S 1 : micro-sphere diameter distribution percentage; S 2 : microspheres drug loading; S=S 1 +S 2 PLGA PLGA [11-12] PLGA 26% 28% 100 mg30 mg 1h 35% 60 mg ph=7.4 PBS 3 ml 30 ml ph=7.4 PBS ml 30 ml [ HPLC LC-10A, Shim-pack VP-ODS (5 µm 250 mm 4.6 mm)] b: PLGA microsphere carrying isoniazid Figure 1 Light microscope images of poly(lactic-co-glycolic acid) (PLGA) copolymer microspheres carrying rifampicin and isoniazid ( 10) 1 ( 10) PLGA ( ) A 2 B 3 C 1 D 2 A 2 B 3 C 1 D 2 3 PLGAPLGAPLGA ( μm) 60% 26% PLGA( μm) 65% 28% 50% 2a 2b 7128

4 d 90 d mg/l3 3 a: Artificial cross-sectional digital image b: Digital photo of artificial bone after in vitro degradation Figure 2 Digital images of two-component drug artificial bone 2 Drug concentration (mg/l) Time (d) RFP: rifampicin; INH: isoniazid RFP INH Figure 3 In vitro drug release curve of two-component drug artificial bone 3 [14] [15] (PLGA) PLGA Sachs [16-17] PLGA 90 d mg/l [18] 4 [1] Huang JS,Shen M,Sun YL,et al.zhonghua Jiehe he Huxi Zazhi. 2000;23(10): ,,,.[J].,2000,23(10): [2] Wang X,Jing X,Cui HC.Zhongguo Jiaoxing Waike Zazhi. 2005; 13(24): ,,. [J].,2005,13(24): [3] Xu PY.Yixue Zongshu. 2010;16(19): [J].,2010,16(19): [4] Zhang H,Jiang SW.Zhongguo Yixue Kexueyuan Xuebao. 2009;31(4): ,.[J].,2009,31(4): [5] Xu XQ.Xibu Yixue. 2011;23(12): [J].,2011,23(12): [6] Huang JT.Yaowu Buliang Fanying Zazhi.2010;12(3): [J].,2010,12(3): ISSN CN /R CODEN: ZLKHAH 7129

5 [7] Zhang WL,Wang Y,Bao YC.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(3): ,,. [J].,2011,15(3): [8] Yang YN,Lou L,Liang QZ,et al.gaodeng Xuexiao Huaxue Xuebao. 2004;125(1): ,,,. [J].,2004,125(1): [9] Luo PP,Zuo Y,Sun B,et al.gongneng Cailiao. 2011;2(8): ,,,. [J].,2011,2(8): [10] Zhang S,Gao X,Shen K,et al.evaluation of poly(d,l-lactideco-glycolide) microspheres for the lung-targeting of yuanhuacine, a novel DNA topoisomerase I inhibitor.j Drug Target.2009;17(4): [11] Ye XY,Sun X,Jia HW,et al.zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(51): ,,,. / - [J].,2011,15(51): [12] Xie HJ,Li M,Deng Y,et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu.2009;13(51): ,,,.- - : [J].,2009,13(51): [13] Jin H,Wu C,Mei XG.Zhongguo Yaoxue Zazhi. 2006;5(22): ,,. [J].2006,5(22): [14] Liu RZ,Huang JF,Liang JH.Guangxi Zhongyi Xueyuan Xuebao. 2010;3(3):69-70.,,.[J].,2010,3(3): [15] Ye XY,Zhen P,Li XF. Zhongguo Jiaoxing Waike Zazhi. 2010; 18(23): ,,. [J].,2010,18(23): [16] Sachs E,Cima M,Williams P,et al.three-dimensional printing: Rapid tooling and prototypes directly from a CAD model.j Eng Ind.1992;114(4): [17] Wu WG,Zheng QX,Guo XD.Zhongguo Shengwu Yixue Gongcheng Xuebao. 2010;29(1): ,,. - - [J].,2010,29(1): [18] Jiang NX.Beijing:Renmin Weisheng Chubanshe. 1989: [M].3.:,1989: (2010KY10) PLGA PLGA 90 d mg/l PLGA μm PLGA 7130